IMMUNOSCINTIGRAPHY WITH IN-111-SATUMOMAB PENDETIDE IN PATIENTS WITH COLORECTAL ADENOCARCINOMA - PERFORMANCE AND IMPACT ON CLINICAL MANAGEMENT

PURPOSE: The role of immunoscintigraphy with In-111-satumomab pendetid e in the medical and/or surgical management of colorectal cancer patie nts was evaluated in a multicenter trial. METHODS: This 103 patient st udy population included 46 individuals with rising serum carcinoembryo nic antigen levels and otherwise negative diagnostic evaluation, 29 pa tients with known recurrence, presumed to be isolated and resectable, and 28 patients for whom standard diagnostic tests provided equivocal information. RESULTS: No adverse reactions were noted following intrav enous administration of 1 mg of satumomab pendetide radiolabeled with approximately 5 mCi of In-111. Thirty percent of patients developed hu man anti-mouse antibodies postinfusion. In the 84 patients for whom co rrelation with histopathologic, diagnostic, and/or clinical findings w as available, antibody imaging demonstrated a sensitivity of 73 percen t in patients with confirmed tumor (36/49) and negative results for al l 35 patients with no evidence of malignancy. Occult disease was detec ted in 18 patients. CONCLUSION: In-111-satumomab pendetide immunoscint igraphy was helpful in the medical and/or surgical management of 45 (4 4 percent) patients and provided information unavailable from other di agnostic modalities.